… -19-induced ALI/ARDS and non-COVID-19 ALI/ARDS, it is … of GSN treatment need to be
established through well-… , GSN-based therapies may become a reality in the near future, offering …

… cells in the direct ALI/ARDS, surfactant protein D has been … more prominent in the indirect
ALI/ARDS can be confirmed by … supplemental oxygen at ICU transfer, while CS therapy was …

… Pulmonary surfactant proteins are specifically secreted by … pro-inflammation factor during
ALI/ARDS. Extracellular histones … mortality must be included in future new trial because these …

… Future directions and further needs for developing innovative … and reduce the amount of
pulmonary surfactant (PS), leading … , (b) applying MSCs in ALI/ARDS, and (c) regenerative …

… therapies that warrant further testing, and future therapeutic … integrity, attenuation of surfactant
production, and inhibition of … , the therapeutic effectiveness of sivelestat to treat ALI/ARDS …

… ARDS through a temporal analysis of key biomarkers of interest. … Future studies could use
the most promising candidate biomarkers in this study (PAI-1, IL-8, and surfactant protein-D) in …

… At present, no single treatment has been shown to modify the … Exogenous surfactant may
improve oxygenation but, again, … that there may be a future in gene therapy. No such agent is …

… while considering the damaged intestinal barrier and respiratory failure, which undoubtedly
increases the difficulty of the diagnosis and treatment of SAP-ALI/ARDS… inform future studies …

… endogenous substances like surfactant or apoptotic or necrotic cells. At the pulmonary …
factors VIIa and thrombin are found in the injured lungs of patients with ALI/ARDS [79, 80]. …

… by ventilator due to surfactant deficiency and dysfunction, which … the effect of sivelestat
therapy in patients with ALI/ARDS. Six … Future large-scale trials should focus on different disease …